British Pharma giant AstraZeneca will invest $ 2.5 billion in the new Chinese HUB

English Pharmacy Giant Astrazeneca On Friday, in China, Capital Beijing said he would invest $ 2.5 billion in a research and development center.

The new center is expected to receive Astrazeneca’s Beijing workforce for about 1,700 employees.

Beijing comes as part of a partnership with the administrative office of the mayor of the Ministry of Economic Development of the Investment City and Beijing.

Under the transaction, Astrazeneca Biotech firms will include research and development employees with Harbor Biomed and Syneron Bio and will launch a joint venture with biokangtai for market vaccinations.

The central “Beijing will be partner with the best biology and AI science and will be a critical part of our global efforts to bring innovative drugs to patients in the world,” he said.

Last month, Astrazeneca gossip According to Reuters, China may face $ 4.5 million in connection with unpaid import duties.

Astrazeneca shares fell to 1% at 11:13 o’clock in London.

AstraRazeneca’s CEO Pascal Soriot interview CNBC International in London Time and London Time in CNBC International / 7: 30-8 am and 12:30:30 AM.

This broke news story is updated.